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Inflammatory bowel disease appears to result from an abnormal host immune response to the intestinal
microbiota. Experimental models have allowed the dissection of the complex dialog between the host and
its microbiota. Through genetic manipulation of the host genome the immune compartments, cells, mole-
cules, and genes that are critical formaintenance of intestinal homeostasis are being identified. Genetic asso-
ciation studies in humans have identified over 100 susceptibility loci. Although there is remarkable coherence
between the experimental model and the human genetic data, a full understanding of the mechanisms
involved in genetic susceptibility to IBD and of gene-gene and gene-environmental interactions will require
a ‘‘next generation’’ of experimental models.Introduction
Inflammatory bowel diseases (IBDs) constitute a significant
health burden in developed countries impacting the quality of
life of some 1.4 million individuals in North America and 2.2
million individuals in Europe (Loftus, 2004). The two main forms
of IBD are ulcerative colitis and Crohn’s disease, which occur
at a comparable incidence of 3– 20 new cases per 100,000
persons per year in the USA and Canada. and have an equivalent
prevalence in males and females. Although the nature and
anatomical location of the inflammatory pathology differ
between the two disorders, it is thought that both arise as a result
of an abnormal immune response to the intestinal microbiota in
genetically predisposed individuals. In Crohn’s disease inflam-
mation is transmural, can be granulomatous, and occurs in any
part of the gastrointestinal tract although the ileum is mainly
affected, whereas in ulcerative colitis, the pathology impacts
primarily the colonic mucosa (Podolsky, 2002). Since the
1940s, the incidence of IBD has dramatically increased in coun-
tries with a more ‘‘westernized’’ lifestyle, suggesting the influ-
ence of environmental factors, including lifestyle, hygiene, diet,
and use of antibiotics, all of which may alter the microbiota in
favor of disease onset and/or progression (Shanahan and
Bernstein, 2009). Similar to other multifactorial diseases, the
rate of incidence of Crohn’s disease among monozygotic twins
is higher than for dizygotic twins. In addition, familial and ethnic
aggregations and segregation studies also strongly suggest the
influence of genetic factors in the etiology of IBD and more
precisely the presence of recessive genetic determinants with
incomplete penetrance (Cho, 2008). Detailed linkage analyses
in IBD-affected families with genome-wide scanning, and more
recently genome-wide association studies (GWAS), have re-
vealed more than 100 genetic loci that show significant associa-
tion with IBDs (Franke et al., 2010; McGovern et al., 2010).
Although these loci account for only 20% of the estimated
genetic risk for IBD, they point to specific pathways with implica-
tions in intestinal homeostasis. Namely, NOD2-dependent
innate immunity, the inflammasome pathway, autophagy, and
interleukin-23 (IL-23)-IL-17 circuitry have surfaced as potentiallynecessary for epithelial barrier integrity, bacterial handling, and
immune tolerance.
IBD patients are generally treated with anti-inflammatory and
immunosuppressive drugs, antibiotics, and biologicals such as
anti-TNF therapies and/or surgery (Van Assche et al., 2009).
Although managing some symptoms of the disease, these strat-
egies do not cure IBD patients from their periodic and life-long
illness. Alternative approaches aim at modifying the microbiota,
through probiotics or bacteriotherapy (Gareau et al., 2010), or at
modulating the polarity of the immune response as with helminth
therapy (Weinstock and Elliott, 2009). A better understanding of
the etiopathology and mechanistic basis of IBD is thus needed
for the development of novel targeted therapeutics. Experi-
mental animal models of the disease, although not fully repre-
sentative of human IBD, recapitulate aspects of the problem
and have provided important insights into the role of the path-
ways, cells and molecules required for intestinal homeostasis.
Notably, the results of human genetic studies are remarkably
coherent with the data derived from experimental models. In
this review, we examine some of the most commonly used
animal models of IBD—genetic, chemical or induced by immune
cell transfer—and explore their relevance in dissecting mucosal
immunity and mechanisms of intestinal pathologies.
The Host-Microbiota ‘‘Dialog’’
The human body is colonized at birth by a wide spectrum of
microorganisms that numerically exceed host cells by 10-
fold. The intestinal tract is the densest microbial ecosystem
found in nature harboring 500–1000 different species of bacteria,
protozoa, and fungi. Collectively, these microorganisms contain
around 100 times as many genes as there are in the human
genome (Gill et al., 2006), and it is argued that this vast micro-
biome is a strong determinant of health and disease. Our coex-
istence with the microbiota is a dynamic and mutually beneficial
one. In addition to a profound influence on host metabolism
(Ba¨ckhed et al., 2004; Backhed et al., 2005) and intestinal devel-
opment, the commensal flora shapes the immune systemboth at
mucosal surfaces (Hand and Belkaid, 2010; Rescigno, 2009) andImmunity 34, March 25, 2011 ª2011 Elsevier Inc. 293
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enteric pathogenic infections by colonization resistance and by
synthesizing factors promoting mutualism. For instance, poly-
saccharide A produced by Bacteroides fragilis suppresses
IL-17 production in the intestine and promotes the function of
IL-10-producing CD4+ T cells, which confers protection in an
experimental model of colitis induced by Helicobacter hepaticus
(Mazmanian et al., 2008). Similarly, induction of a transforming
growth factor b (TGF-b)-rich environment by indigenous
Clostridium species promotes T regulatory (Treg) cell accumula-
tion in the colon and resistance to colitis (Atarashi et al., 2011).
Sensing of the commensal flora by the innate immune system
is also critical for intestinal homeostasis and tissue repair after
injury. Consistently, depletion of commensal microorganisms
by antibiotics treatment, or deficiency in central innate immunity
effectors such as the NLRP3 inflammasome and its central
enzyme caspase-1, or the Toll-like receptors (TLRs)-IL-1
receptor family (IL-1R and IL-18R) common adaptor MyD88,
impairs mucosal regeneration after injury by oral administration
of dextran sulfate sodium (DSS), which leads to mucosal injury
and colitis (Saleh and Trinchieri, 2011).
Whereas the microbiota is protective and necessary for host
physiology, it becomes a liability when coupled with a physical,
chemical, or immunological insult in genetically predisposed
individuals. For instance, segmented filamentous bacteria
(SFB), found in mice from certain production facilities, promote
Th17 cell development in the intestine, and such development
is linked to local as well as systemic pathologic effects impacting
autoimmunity and cancer (Ivanov et al., 2009; Westbrook et al.,
2009; Wu et al., 2010). Accumulating evidence indicates that
host genotypes reciprocally affect microbiota composition,
which in turn alters host responses. The most striking example
is that of Tbx21/ (Tbx21 encodes the transcription factor
T-bet) Rag2/ (TRUC) mice that develop a spontaneous and
transferrable form of ulcerative colitis (Garrett et al., 2007;
Garrett et al., 2009). Deficiency of T-bet in the innate immune
system leads to exaggerated tumor necrosis factor (TNF)
production by dendritic cells, which together with the absence
of Treg cells creates a chronic inflammatory state that modulates
the composition of the microflora. Specifically, two bacterial
species, Proteus mirabilis and Klebsiella pneumoniae, are asso-
ciated with the transfer of colitis to wild-type mice (Garrett et al.,
2010). Thus, the environment-microbiota-genetics interaction
might explain in part why disease develops in only a small frac-
tion of individuals carrying common risk alleles of disease
susceptibility genes. It is clear that the microbiota is the buffer
between the environment and the host, and much effort is now
invested at deciphering its functionality in health and disease.
Various human microbiome projects including the NIH Human
Microbiome Project (http://commonfund.nih.gov/hmp/) and the
International Human Microbiome Consortium (http://www.
human-microbiome.org/) have been established with the aim
of defining microbes and microbial genes (metagenome) that
are present at different anatomical sites.
The Role of the Intestinal Epithelial Barrier
in Gut Homeostasis and Pathologies
Intestinal epithelial cells and the barrier they form are critical for
host-microbiota mutualism in the gut. Various animal models294 Immunity 34, March 25, 2011 ª2011 Elsevier Inc.derived primarily from gene targeting approaches and/or chem-
ical models of colitis (e.g., DSS) have investigated the role of the
epithelial barrier in intestinal homeostasis and have revealed
critical epithelial mechanisms deregulated in IBD (Table 1). The
intestinal epithelium is composed of a single layer of intestinal
epithelial cells (IECs), including absorptive enterocytes, goblet
cells, Paneth cells, and enteroendocrine cells, which collectively
cover a surface area of 400 m2, tightly packed into numerous villi
and crypts. The integrity of this barrier is crucial to shield the host
from commensal microorganisms and foodstuffs in the intestinal
lumen and to prevent pathologic antigen-specific immune
responses, as evident in IBD and celiac disease.
Each IEC subtype contributes to barrier integrity through
specialized mechanisms (Figure 1). The enterocytes migrate
out of the crypts to form the surface epithelium and ensure
barrier function through an apical brush border and intercellular
tight junctions. Targeted disruption of tight junctions in geneti-
cally modified mice results in increased susceptibility to chemi-
cally induced colitis (Su et al., 2009), which is consistent with
observations of altered tight junction expression and/or localiza-
tion in IBD patients (Mankertz and Schulzke, 2007). Goblet cells
reinforce the enterocyte fence by producing mucus that forms
a protective polysaccharide glycocalyx bilayer, in which the
firm inner layer is devoid of bacteria (Johansson et al., 2008).
Gene-targeting approaches of Muc1 or Muc2, which encode
key constituents of mucus, have similarly highlighted the critical
role of this physical barrier in preventing disease onset. It has
been shown that Muc1 ablation enhances small intestinal
damage after infection with C. jejuni (McAuley et al., 2007) and,
more strikingly, mucin-2-deficiency results in spontaneous
chronic colitis and colitis-associated colorectal cancer (Heazle-
wood et al., 2008; Van der Sluis et al., 2006; Velcich et al., 2002).
Notably, altered expression and glycosylation of mucin-1 have
been reported in IBD (Campbell et al., 2001), and MUC1 is one
of the newly implicated loci in Crohn’s disease pathogenecity
(Franke et al., 2010).
Paneth cells produce antimicrobial peptides including a-de-
fensins (cryptidins), b-defensins, and cathelicidins, and modula-
tion of a-defensin expression or their maturation bymatrix metal-
loproteinase (MMP)-7 in genetically modifiedmice have revealed
an important homeostatic role of defensins on intestinal micro-
bial ecology (Salzman et al., 2010). Indeed, transgenic expres-
sion of human a-defensin 5 (HD5) in mice has led to significant
reduction in SFB and IL-17-producing T cells in the lamina prop-
ria, which is in support of earlier findings that Crohn’s disease
patients exhibit defective defensin production (Wehkamp et al.,
2005).
For ensuring barrier integrity, the epithelial layer is constantly
renewed through daily cycles of IEC proliferation, migration,
and apoptosis along the crypt-villus axis, and disruption of these
homeostatic processes is linked to disease. For instance, tar-
geted mouse strains with defects in IEC survival, through abla-
tion of the NF-kB pro-survival pathway, develop spontaneous
IBD-like intestinal pathologies. Notably, enterocyte-specific
deletion of NF-kBessential modulator (NEMO) or both IkB kinase
(IKK) a and IKKb leads to spontaneous IEC apoptosis and
massive intestinal inflammation (Nenci et al., 2007). Inhibition
of TNFR1 signaling in these mice prevents IEC apoptosis and
the consequent development of intestinal inflammation, which
Table 1. Experimental Models of Colitis
Gene Involved Mechanism Microbiota or Environment
Spontaneous
TRUC Tbx21/Rag2/ [TNF (innate) YTreg (adaptive) klebsiella pneumonia,
proteus mirabilis
MUC2 Muc2/ Ymucin (epithelial) _
NEMO IkbkgIEC [apoptosis (epithelial) _
IKKa and IKKb Ikbka-IkbkbIEC [apoptosis (epithelial) _
MDR1 Abcb1b/ [xenobiotic substances (epithelial) _
TGF-b Tgfb1/ YTreg (adaptive) _
TGF-bRII Tgfbr2/ YTreg (adaptive) _
IL-10 Il10/ YTreg (adaptive) _
IL-10R1 Il10r1/ YTreg (adaptive) _
IL-2 Il2/ YTreg (adaptive) _
FOXP3 Foxp3/ YTreg (adaptive) _
Microbial
H. hepaticus _ [Th17 (adaptive) bacteroides fragilis
(protective-[IL-10-YIL-17)
segmented filamentous
bacteria (SFB)
_ [Th17 (adaptive) _
C. jejuni Muc1 Ymucin (epithelial) _
H. hepaticus Nod2 Ydefensin (epithelial) HD5IEC transgenic
(protective)
_
Chemical
DSS
Tnfaip3IEC [apoptosis (epithelial) _
Tlr2/, Tlr4/ Ytissue repair (innate) _
Myd88/ Ytissue repair (innate) _
Nlrp3/ Ytissue repair (innate) _
Casp1/ Ytissue repair (innate) _
Il18/ Ytissue repair (innate) _
Il18r1/ Ytissue repair (innate) _
Nod2+/+ MDP protective, [tissue repair (innate) _
_ clostridium species
(protective-[TGF-b-[Treg)
Atg16l1/ [inflammasome (innate)
Atg16l1HM YPaneth cell function norovirus + microbiota
Immune
CD4+CD45+Rb(hi) transfer
Mylk transgenic disrupted tight junctions (epithelial) _
Stat4 transgenic [Th1 (adaptive)
_ IL-23 neutralization, protective YTh17 (adaptive) _
_ CD4+CD25+ cotransfer ([Treg), protective
(adaptive)
_
microbiota-reactive memory
CD4+ Th1 cells transfer
_ [Th1 (adaptive)
microbiota-reactive memory
CD4+ Th17 cells transfer
_ [Th17 (adaptive)
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the TNF pathway on restoring barrier function in IBD patients
(Zeissig et al., 2004). Consistently, IEC-specific deletion of
TNFAIP3 (encoding A20), a gene mutated in Crohn’s disease(Wellcome Trust Case Control Consortium, 2007) that encodes
an E3 ligase-editing enzyme involved in dampening NF-kB
signaling and TNF-induced apoptosis, leads to massive IEC
apoptosis and increased susceptibility to experimental colitisImmunity 34, March 25, 2011 ª2011 Elsevier Inc. 295
Figure 1. Mechanisms of Intestinal
Homeostasis with the Microbiota
Intestinal homeostasis is maintained through
a dialog between the host immune system (innate,
adaptive, and regulatory) and the microbiota,
a crosstalk modified by host genetics (e.g.,
susceptibility loci identified by GWAS) and envi-
ronmental triggers (e.g., DSS, norovirus, and
H. hepaticus). Various commensal bacterial
species enhance mutualism with the host (e.g.,
Bacteroides fragilis and clostridium species) and
others induce intestinal pathology (e.g., SFB,
Klebsiella pneumonia and Proteus mirabilis).
Epithelial defenses include mucus production by
goblet cells, defensin production by paneth cells
and colonocytes, intact tight junctions between
intestinal epithelial cells (IECs), IEC antiapoptotic
mechanisms, and autophagy. Pattern recognition
receptors of the innate immune system, including
TLRs, NLRP3, and NOD2, sense microbial and
danger motifs and are required for mucosal
regeneration and tissue repair. In addition, they are
necessary for activation and sculpting of the
adaptive and regulatory immune responses.
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illustrates the link between impaired IEC integrity and IBD is
that of defective multidrug resistance (MDR) 1 function. Defi-
ciency in MDR1, a trans-membrane P-glycoprotein involved in
xenobiotic substances transport and removal, results in sponta-
neous development of severe IBD, which is dependent on the
microflora and the nonhematopoietic compartment of the gut,
as revealed by bone marrow chimera experiments (Panwala
et al., 1998).
Crosstalk of ‘‘First Responders’’ Innate Immune
Cells with the Microbiota
It is increasingly appreciated that intestinal homeostasis and IEC
barrier integrity are a function of the crosstalk between the mi-
crobiota and the innate immune system. The latter is equipped
with a variety of pattern-recognition receptors (PRRs) expressed
inmyeloid cells as well as IECs including among others TLRs and
Nod-like receptors (NLRs) that sense microbial-associated
motifs and/or host-derived damage signals and trigger a physio-
logical level of inflammation that favors stem cell proliferation,
IEC survival, and restitution (Saleh and Trinchieri, 2011). The
acute DSS model is useful for the study of innate immune mech-296 Immunity 34, March 25, 2011 ª2011 Elsevier Inc.anisms of colitis and tissue repair. DSS,
a sulfated polysaccharide administered
to mice in drinking water, is directly cyto-
toxic to enterocytes of the basal crypts
and leads to barrier damage, microbial
translocation, and induction of a colitis
phenotype that is independent of the
adaptive immune system (Dieleman
et al., 1994). In contrast to DSS, colitis
induced with the haptens TNBS, DNBS,
or oxazolone instilled into the colon
depends both on an acute oxidative injury
with innate activation and on CD4+
T cell stimulation by autologous or micro-
bial antigens (reviewed in Wirtz andNeurath, 2007). With the DSS model, it has been recently
demonstrated that similarly to TLRs (Rakoff-Nahoum et al.,
2004), the Nlrp3 inflammasome-caspase-1-IL-18-IL-18R-
MyD88 axis of innate immunity is required for tissue repair and
protection from colitis (Allen et al., 2009; Dupaul-Chicoine
et al., 2010; Salcedo et al., 2010; Zaki et al., 2010). MyD88-
dependent signaling regulates the positioning of prostaglandin-
endoperoxide synthase 2 (Ptgs2)-expressingmesenchymal cells
to the base of the crypt surrounding colonic epithelial progeni-
tors, which is needed for their compensatory proliferation after
damage (Brown et al., 2007). Consistent with the protective
role of the Nlrp3 inflammasome pathway in experimental models
of colitis, a single-nucleotide polymorphism (SNP) in the 30 region
of the human NLRP3 gene, which confers decreased NLRP3
expression, is associated with Crohn’s disease in individuals of
European descent (Villani et al., 2009). However, the healing
role of innate immunity in the gut is not confined to the TLR
and inflammasome pathways (Figure 1). Indeed, CARD15 that
encodes the cytosolic peptidoglycan receptor NOD2 was the
first susceptibility gene identified for Crohn’s disease (Hugot
et al., 2001; Ogura et al., 2001). With the DSS model, it has
been shown that stimulation of this pathway through
Immunity
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(MDP) protected experimental mice from colitis (Watanabe et al.,
2008), arguing for a role of NOD2 in mucosal regeneration.
Through the generation of two NOD2-deficient mice (Kobayashi
et al., 2005; Watanabe et al., 2004) and one human CARD15
gene knock-inmouse (Maeda et al., 2005), NOD2 has been impli-
cated in a number of additional homeostatic processes in the
intestine including the production of defensins (Biswas et al.,
2010; Wehkamp et al., 2004), the polarization of the adaptive
immune response toward a Th2 cell-type cellular response
(Magalhaes et al., 2008), and the control of autophagy (Cooney
et al., 2010; Travassos et al., 2010); however, the exact mecha-
nisms of NOD2 actions remain unclear (see below). PRR sensing
of the microbiota in the gut thus leads to multiple mechanisms
that collectively contribute to intestinal homeostasis: through
activation of central inflammatory pathways, including NF-kB,
MAPK, and inflammasome pathways, PRR signaling drives the
synthesis of mitogenic factors, including IL-6, IL-11, IL-18,
COX-2, and antiapoptotic factors, such as BCL-XL, which stim-
ulate IEC proliferation and survival, respectively (Saleh and Trin-
chieri, 2011). In addition, PRRs control microbial ecology in the
gut through the regulation of defensin production (Biswas
et al., 2010; Wehkamp et al., 2004), and modulate the adaptive
immune response by stimulating the expression of factors that
direct Th cell differentiation (see below).
CD4+ T Cell Response to Microbiota in Intestinal
Inflammation
Early studies demonstrated that the critical effector cell in most
models of experimental colitis that involve the adaptive immune
system is the CD4+ T cell (Elson and Weaver, 2009). Although
CD4 Th1, Th2, and Th17 effector cell subsets can all cause
colitis, there are only a few instances in which CD4+ Th2 cells
mediate colitis; the most studied being the TCRa-deficient
mouse (Mizoguchi et al., 2000). In this model a CD4+ TCRb
homodimer-positive cell produces IL-4 and mediates disease
(Takahashi et al., 1997).
Other models in which Th2 cells or cytokines have been impli-
cated include oxazalone colitis in SJL mice (Boirivant et al.,
1998), Wiskott Aldrich syndrome protein-deficient mouse colitis
(Nguyen et al., 2007), and the chronic phase of ileitis in SAMP1/
Yit ileitis (Bamias et al., 2005). These are quite different models
and it is unknown whether they share any common pathway
that activates pathogenic Th2 effector cells. Candidate mole-
cules for such a role might include NOD2 and thymic stromal
lymphopoeitin (TSLP), which have been shown in humans to
modulate dendritic cells to promote Th2 cell responses (Butler
et al., 2007; Rimoldi et al., 2005).
Among the models useful for studying effector T cell mecha-
nisms in IBD, the most fertile has been the adoptive transfer of
CD45RBhi CD4+ naive or CD4+ bacterial-reactive memory
T cells into immunodeficient recipients (Cong et al., 1998; Powrie
et al., 1994). After such transfer the colitis that ensues is marked
by increased production of IL-12p70 and IFN-g in the lesions.
Transfer of T-bet-deficient CD4+CD45RBhi cells does not result
in colitis, supporting an important role for CD4+ Th1 cells in
disease pathogenesis (Neurath et al., 2002). IL-12p70 signals
Th1 cells via the transcription factor STAT4, and STAT4 trans-
genic mice have been generated (Wirtz et al., 1999). Thesemice develop Th1cell-mediated colitis only after an immunization
that activates innate antigen-presenting cells and adaptive CD4+
T cells, indicating a role for both cell types in the pathogenesis.
An important role of innate cells in T cell transfer colitis has
been shown by a recent study demonstrating that expansion in
the numbers of the transferred CD4+ T cells by homeostatic
proliferation in the recipients is absolutely required for colitis
and that this expansion in numbers is dependent on microbiota
stimulation of IL-6 secretion via an innate MyD88-dependent
mechanism (Feng et al., 2010). Interestingly, a second critical
requirement for transfer colitis is the activation and differentiation
of the transferred T cells by microbiota antigens (Feng
et al., 2010). When both requirements are met, proliferation
and differentiation of Th1 and Th17 effector cells occur and result
in colitis.
The role of the CD4+ Th17 cell subset in experimental colitis
has been recognized more recently (Hue et al., 2006; Yen
et al., 2006). T cell transfer into IL-23-deficient Rag1/ mice
does not result in colitis (Hue et al., 2006), and neutralization of
IL-23 reverses active colitis (Elson et al., 2007). IL-23 is produced
by innate immune cells and has effects on both innate and adap-
tive cells. Among CD4+ cells, Th17 cells have receptors for IL-23
and are dependent on IL-23 for maintenance and survival. Trans-
fer of microbiota-reactive memory CD4+ Th17 cells induced
colitis at 1/10 the dose than did transfer of CD4+ Th1 cells,
indicating that the Th17 cell subset has potent colitogenic
activity (Elson et al., 2007). Interestingly, during active colitis,
the lamina propria contains CD4+ T cells expressing both IL-17
and IFNg. Recent data indicate that CD4+ Th17 cells can convert
to this double-positive subset and then to IL-17-IFNg+ Th1 cells,
both in vitro and in vivo (Lee et al., 2009). This Th17 cell plasticity
is dependent on the cytokine milieu. In contrast, conversion of
Th1 cells to Th17 cells has not yet been observed. IL-17 and
IL-23 are increased in the lesions of patients with Crohn’s
disease, but so are IFNg and IL-12 (Fujino et al., 2003; Fuss
et al., 2006). Although the data are clear that both Th1 and
Th17 cells can mediate colitis, the role that each subset plays,
when and how each contributes, and the consequences of
Th17 cell plasticity all remain to be elucidated.
CD4+ Th effector cells have specific receptors that respond to
antigen-MHC, raising the question of which microbiota antigens
drive IBD. It is known that there is an increased adaptive immune
response, in the form of serum IgG or IgA antibodies to a small
set of microbial antigens in humans with IBD (Mow et al.,
2004). Serologic expression cloning was thus used to identify
the microbiota antigens involved in a mouse model of sponta-
neous colitis (Lodes et al., 2004). A limited number of protein
antigens were found, among which one quarter were previously
unknown bacterial flagellins. Interestingly, half of patients with
Crohn’s disease, but not those with ulcerative colitis or controls,
had reactivity to the prototypic flagellin of this cluster, named
CBir1. Both colitic mice and humans with Crohn’s disease had
increased CD4+ T cell reactivity to CBir1 flagellin (Lodes et al.,
2004; Shen et al., 2008). Seroreactivity to CBir1 in patients with
Crohn’s disease correlates with a more complicated course of
disease and a need for surgery (Targan et al., 2005). The sharing
of CD4+ T cell and B cell reactivity to flagellin in both mouse and
humans indicates that the abnormal adaptive T cell response in
both species may be remarkably similar.Immunity 34, March 25, 2011 ª2011 Elsevier Inc. 297
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Homeostasis and Inflammation
As discussed, the innate compartment of the intestine provides
a microenvironment that promotes the induction of Treg cells
in the intestine (Barnes and Powrie, 2009; Rescigno andDi Saba-
tino, 2009). These Treg cells are largely directed at microbiota
and food antigens. TGF-b and retinoic acid are two factors that
are enriched in the intestine that promote the induction of Treg
cells. The importance of Treg cells in maintaining intestinal
homeostasis has been demonstrated by the targeted deletion
of certain genes expressed by Treg cells, which results in colitis
in conventionally reared but not germ-free mice, including those
that encode TGF-b, TGF-bRII, IL-10, IL-10R1, IL-2, and Foxp3
(Elson and Weaver, 2009). Under homeostatic conditions, the
gut lamina propria has the largest proportion of CD4+ Treg cells
of any tissue, including Foxp3+IL-10, Foxp3+IL-10+, and
Foxp3IL-10+ (Tr1) cells (Maynard et al., 2007). Other cell types
have also been implicated in intestinal regulation, including gd
T cells, CD8+ T cells, NK cells, and B cells, and these cells can
cooperate; for example’ Foxp3+ Treg cells interact with IgA+ B
cells in the intestine to reduce the uptake of microbiota antigens
and prevent systemic T cell activation (Cong et al., 2009)
(Figure 1). Among CD4+ Treg cells, both thymus-derived natural
Foxp3+ Treg cells and peripherally induced Foxp3+ Treg cells are
required to maintain intestinal homeostasis (Haribhai et al.,
2009).
The adoptive T cell transfer model has demonstrated that
cotransfer of CD4+CD25+ Treg cells with CD4+CD45RBhi
T cells prevents colitis (Asseman et al., 1999). The exact mecha-
nism by which Treg cells do so remains undefined, but Treg cells
deficient in the mucosal a4b7 integrin homing receptor are
effective (Denning et al., 2005), indicating that Treg cells can
exert their inhibitory effects outside the intestinal lamina propria,
possibly by inhibiting spontaneous proliferation of the adoptively
transferred CD4+CD45RBhi T cells (Feng et al., 2010). Although
transfer of large numbers of CD4+CD25+ Treg cells to mice
with active colitis can quell inflammation and restore homeo-
stasis, this takes many months to occur (Mottet et al., 2003).
Thus, Treg cells are much more effective at preventing colitis
than at reversing it once established. In the absence of critical
molecules such as IL-10 or TGF-b, Treg cells are not able to
prevent colitis, which develops spontaneously, is progressive,
and is ultimately fatal.
The relative ineffectiveness of Treg cells during active inflam-
mation is due to a number of mechanisms. First, TLR ligand-
induced inflammatory cytokines such as IL-6 make T effector
cells more resistant to inhibition (Pasare and Medzhitov, 2003).
More recently, it has been recognized that CD4+ Treg cells can
convert to effector CD4+ phenotypes such as Th1- or Th17-type
cells in inflamed tissues (Oldenhove et al., 2009; Wohlfert and
Belkaid, 2010). The inflammatory milieu may determine which
CD4 subset Treg cells convert into; e.g., a Th1 cell-dominated
inflammation appears to induce Foxp3+ IFN-g+ T cells, and it
has been proposed that such converted Foxp3+ IFN-g+ T cells
may be more effective in dampening Th1 cell-mediated inflam-
mation (Belkaid and Rouse, 2005). In other systems using
Rosa26 lineage tracing, Treg cells have been shown to convert
completely into CD4+ effector T cell subsets that then contribute
to inflammation (Zhou et al., 2009). Similar conversion probably298 Immunity 34, March 25, 2011 ª2011 Elsevier Inc.also occurs in IBD. Such plasticity may explain why Treg cells
are more effective at preventing IBD than in reversing it.
Why have mechanisms evolved to overrule Treg cell function
during active inflammation or, put another way, what are the
roles of Treg cells in the intestine? The answer to this question
is best viewed in the context of intestinal infections, which
have probably exerted evolutionary selection on the develop-
ment of Treg cells. The microbiota are an effective barrier to
pathogens. Interestingly, enteric pathogens such as Salmonella
andCitrobacter actively induce intestinal inflammation, which, in
turn, alters microbiota composition, reducing strict anaerobes
such as the Firmicutes, and allowing proteobacteria, including
these pathogens, to expand (Lupp et al., 2007; Stecher et al.,
2007). Treg cell inhibition of such inflammation would oppose
such changes in the microbiota, thus maintaining colonization
resistance. However, once the pathogen is established and the
immune response is engaged, the role of Treg cells is thought
to be mainly in the limitation of tissue damage (Belkaid and
Rouse, 2005). The ability of Treg cells to convert to effector
phenotypes indicates that they serve a second role, that of
a ‘‘ready reserve’’ that be called upon to bolster the effector
response to the pathogen and protect the host.
How do these models apply to human IBD? Treg cells are
more difficult to study in humans because there are no truly
specific markers to identify them. Given that limitation, the
proportion and ex vivo function of Treg cells in human IBD are
normal (Holme´n et al., 2006; Maul et al., 2005; Saruta et al.,
2007). It is unknown whether human Treg cells lose function or
convert to effector T cell subsets in vivo. Yet a SNP in the IL10
gene confers susceptibility to both Crohn’s disease and ulcera-
tive colitis (Franke et al., 2010; McGovern et al., 2010), andmuta-
tion in the IL10R gene resulted in early onset in IBD in two
kindreds (Glocker et al., 2009). Whether defects in Treg cells
contribute to human IBD remains an open question, but if so, it
is likely to be a relative deficiencymanifest mainly in the intestine.
The ‘‘Next Generation’’ of Experimental Models of IBD
Over the past two decades, gene targeting in mice has identified
many genes that are required for maintenance of intestinal
homeostasis and prevention of inflammation. Many of these
gene-targeted mouse lines have added greatly to our under-
standing of the pathogenesis of IBD. The IBD phenotype of
mice with the same gene deficiency but on different genetic
backgrounds varies markedly (Bristol et al., 2000) because of
gene modifiers (Beckwith et al., 2005). The C57Bl6 strain, which
is now commonly used, is relatively resistant to colitis. Similar
genetic variation exists in humans, as has been demonstrated
by GWAS of IBD (Franke et al., 2010; McGovern et al., 2010).
Understanding the mechanisms by which the human gene loci
uncovered by GWAS confer susceptibility to IBD will require
a ‘‘next generation’’ of experimental models. This will be chal-
lenging because human genes are not likely to be globally defi-
cient, but rather relatively impaired in function and this will
need to be factored into the models.
Mouse models have been used to study several of the human
susceptibility genes. For instance, two NOD2-deficient mice and
a NOD2 (CARD15) knock-in mouse have been generated, but no
consensus on the exact mechanism of theCARD15 gene abnor-
mality has been achieved. Studies on human cells with theNOD2
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Reviewmutation revealed a function of NOD2 in inducing IL10 gene tran-
scription, a role not conserved for the mouse orthologs (Noguchi
et al., 2009). Furthermore chronic stimulation of human cells re-
vealed abnormalities not observed with acute stimulation
(Hedl et al., 2007). Because IBD is a chronic disease, design of
experiments and experimental models will need to allow for
these potential confounders.
The gene that encodes IL-23 receptor is strongly associated
with Crohn’s disease and ulcerative colitis in GWAS studies, as
are multiple genes in the IL-23 pathway (Cho and Weaver,
2007). IL-23 has effects on both innate and adaptive immune
cells and in mice its effects are most prominent in the intestine
(Uhlig et al., 2006). IL-23p19 was first cloned in the mouse and
has been shown to be required for colitis to develop in multiple
models (Yen et al., 2006). Neutralization of IL-23 completely
reversed active colitis in one model (Elson et al., 2007), which
is consistent with data showing that the dominant IL23R SNP,
which is protective in IBD, encodes for an alternative splicing
of the gene, resulting in a soluble receptor antagonist of IL-23
(Yu and Gallagher, 2010). Thus, mouse and human studies on
the role of IL-23-Th17 cell pathway in IBD are remarkably conver-
gent and are likely to lead to new therapeutic approaches.
Indeed, therapeutic trials on IL-23p19 monoclonal antibodies
are underway in Crohn’s disease.
Discovery that ATG16L1, an autophagy gene, conferred
susceptibility for Crohn’s disease was unexpected (Hampe
et al., 2007; Rioux et al., 2007). The ATG16L1 SNP is a common
genetic variation present in 40%–50%of the population, thus the
vast majority of persons with this SNP do not develop IBD. The
Atg16l1 gene has been deleted in mice, but is embryonic lethal.
Cells obtained from embryos of Atg16L1-deficient mice ex-
hibited heightened inflammasome activation and IL-1b produc-
tion when stimulated with LPS (Saitoh et al., 2008). Studies in
mice that are hypomorphic, but not completely deficient in
Atg16L1 (Atg16l1HM;1%of normal expression), have identified
abnormalities in ileal Paneth cells consisting of abnormal inclu-
sions and escape of antimicrobial peptides, such as lysozyme,
into the cytoplasm. Interestingly, similar abnormalities of Paneth
cells have been found in ileal tissue of Crohn’s disease patients
but only in those who have the ATG16L1 SNP (Cadwell et al.,
2008). Subsequent studies in Atg16l1HM have shown that murine
norovirus infection is required for the Paneth cell phenotype to
express, even though the Paneth cells themselves are not in-
fected by this virus (Cadwell et al., 2010). Although there was
no spontaneous inflammation in norovirus-infected Atg16l1HM
mice, these mice were more susceptible to DSS, leading to
a TNF-dependent phenotype resembling aspects of IBD
(Cadwell et al., 2010). These studies are among the first to reveal
an important interaction among environmental components,
namely norovirus infection and the microbiota, with the
ATG16L1 gene variant, with both components being required
for the IBD susceptibility phenotype. This is notable because
environmental factors are known to be major contributors to
IBD susceptibility, but the identity and mechanisms of these
environmental factors is largely unknown. A human intestinal
virome has been described recently, which was unique to each
individual studied (Reyes et al., 2010). The contribution of the
gut virome to IBD and to the variability in disease course among
individuals has not yet been explored.At present only a few IBD susceptibility genes have resulted in
gene-targeted mice and mechanistic studies. Although gene-
deficient mice can be useful for such studies, to understand
the role of these genes in humans, conditional deletion and
inducible gene knockin mouse models will be needed. These
are more complex to generate but the technology exists and is
fairly widely available. Such models will be necessary to under-
stand the complex gene-gene and gene-environment interac-
tions that contribute to IBD. Stressors such as DSS may be
needed for these next generationmodels, butwill not be a substi-
tute for them. The recent discovery that the NOD2 gene regu-
lates autophagy is an example of the potential importance of
gene-gene interactions in IBD susceptibility (Cooney et al.,
2010; Travassos et al., 2010). Adding to this complexity, it is clear
that the composition of the microbiota can impact the immune
system in major ways, and thus the microbiota composition of
various models will need to be defined and controlled in these
next generation models.REFERENCES
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